Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123050 | 0.91 | GABRA1 (0.42) | ALDH1A1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL8583296 | 0.83 | ALDH1A1 (0.48) | NPY5RALDH1A1TSHRMAPTPOLB | |
| SCHEMBL15248076 | 0.83 | GABRA1 (0.40) | NPY5RALDH1A1TSHRMAPTPOLB | |
| SCHEMBL8564692 | 0.81 | PTGS1 (0.43) | TSHRMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8536061 | 0.81 | GABRA1 (0.51) | ALDH1A1SMN1; SMN2GABRA1GABRG2GABRB3 | |
| SCHEMBL8533901 | 0.80 | ADORA2A (0.44) | ALDH1A1MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL8233681 | 0.76 | NPC1 (0.50) | ALDH1A1TSHRPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL6122151 | 0.76 | GABRA1 (0.40) | ALDH1A1POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL6122430 | 0.75 | GABRA1 (0.39) | ALDH1A1TSHRPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL6121774 | 0.75 | GABRA1 (0.39) | ALDH1A1MAPTGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801879-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801879-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3034079-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2640391-B1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9145372-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145372-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014153180-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GALLAGHER MICHELA (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014078377-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | AGENEBIO, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068161-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | NPY5R 46/4885ALDH1A1 2259/4885TSHR 582/4885 |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | NPY5R 46/4885ALDH1A1 2259/4885TSHR 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.